Inhibition of Growth in Ovarian Cancer Cells by ZM 252868
Author Information
Author(s): Simpson B J B, Bartlett J M S, Macleod K G, Rabiasz G, Miller E P, Rae A L, Gordge P, Leake R E, Miller W R, Smyth J, Langdon S P
Primary Institution: Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospitals NHS Trust, Edinburgh, EH4 2XU, UK
Hypothesis
Can the tyrosine kinase inhibitor ZM 252868 inhibit TGF-α-mediated growth effects in ovarian cancer cell lines?
Conclusion
The study found that ZM 252868 can effectively inhibit the growth of ovarian carcinoma cells in vitro by blocking tyrosine phosphorylation at the EGF receptor.
Supporting Evidence
- ZM 252868 completely inhibited TGF-α-stimulated growth in PE01 and PE04 cell lines at concentrations ≥ 0.3 μM.
- In SKOV-3 cells, TGF-α growth was inhibited by ZM 252868 at concentrations ≥ 0.1 μM.
- The inhibitor reversed TGF-α inhibition of PE01CDDP growth at concentrations ≥ 0.1 μM.
- ZM 252868 completely inhibited TGF-α-stimulated tyrosine phosphorylation of the EGF receptor.
Takeaway
This study shows that a drug called ZM 252868 can stop certain cancer cells from growing by blocking signals that tell them to grow.
Methodology
The effects of ZM 252868 on cell growth and signaling were evaluated in four ovarian carcinoma cell lines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website